GlassScriptPhysician profile
Rachit Kumar
NPI 1821313966
$3,566.23
in general payments reported to CMS, 2019-2025
25 companies · $16.73 in 2025
The $16.73 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $133 · 2021: $804 · 2022: $933 · 2023: $431 · 2024: $22.01 · 2025: $16.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Entertainment: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.93 |
| Entertainment | $135.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $970.69 | 2019-2023 | Flexitron Hdr, Elekta Medical Linear Accelerator |
| Viewray Technologies INC | $647.42 | 2021-2022 | |
| Varian Medical Systems, INC. | $584.26 | 2019 | |
| Palette Life Sciences, INC. | $284.58 | 2022 | |
| Sirtex Medical INC | $188.93 | 2019 | |
| Zap Surgical Systems, INC. | $166.30 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $129.11 | 2021-2022 | |
| Medtronic USA, INC. | $101.69 | 2019 | |
| Reflexion Medical, INC. | $95.59 | 2023 | Reflexion Medical Radiotherapy System |
| Angiodynamics, INC. | $56.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $52.88 | 2019 | |
| Seagen INC. | $33.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.66 | 2019-2020 | |
| Accuray Incorporated | $24.43 | 2019 | |
| Karyopharm Therapeutics INC. | $23.85 | 2023 | Xpovio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.49 | 2019 | |
| Genzyme Corporation | $22.67 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $22.53 | 2019 | |
| Gilead Sciences, INC. | $22.01 | 2024 | |
| Amgen INC. | $19.02 | 2019 | |
| Merck Sharp & Dohme LLC | $16.73 | 2025 | Keytruda |
| Janssen Biotech, INC. | $15.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.59 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2020 | |
| Pfizer INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachit Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.